Trial Profile
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Aug 2023
Price :
$35
*
At a glance
- Drugs Letetresgene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
- Indications Synovial sarcoma
- Focus Therapeutic Use
- Acronyms NY-ESO-1
- Sponsors GlaxoSmithKline; GSK
- 27 Jul 2020 This trial has been completed in United Kingdom, according to European Clinical Trials Database record.
- 26 Feb 2020 Status changed from active, no longer recruiting to completed.
- 12 Jun 2019 Planned number of patients changed from 10 to 45.